Insight Molecular Diagnostics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMDX research report →
Range $1 – $1
Price Chart
About the company
Insight Molecular Diagnostics Inc. functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories.
- CEO
- Joshua Riggs
- IPO
- 2015
- Employees
- 57
- HQ
- Nashville, TN, US
Get TickerSpark's AI analysis on IMDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $64.53M
- P/E
- -1.54
- PEG
- -0.02
- P/S
- 32.77
- P/B
- -3.00
- EV/EBITDA
- -1.41
- Div Yield
- 0.00%
- Gross Margin
- 23.74%
- Op Margin
- -1795.78%
- Net Margin
- -2137.33%
- ROE
- 192.10%
- ROIC
- -255.37%
Latest fiscal year · YoY change
- Revenue
- $4.05M+115.6%
- Gross Profit
- $190.00K-74.3%
- Op Income
- $-30,578,000
- Net Income
- $-50,222,000+17.2%
- EPS
- $-1.65+64.6%
- OCF Growth
- -7.1%
- FCF Growth
- -19.5%
- 52W High
- $7.51
- 52W Low
- $1.50
- 50D MA
- $3.05
- 200D MA
- $4.41
- Beta
- 1.86
- RSI (14)
- 35
- Avg Volume
- 261.88K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Insight Molecular Diagnostics said it is nearing the final steps of its FDA de novo process for GraftAssureDx while starting early revenue-building activities through registry and beta-site programs.· November 16, 2026
- GALACTIC registry enrollment has started, with UCLA first in; management says about 5 sites should be enrolling by year-end and more in Q1.
- The company says FDA review is in its final stretch after a late-July additional information request, and it expects to submit a complete response before the January 21, 2027 deadline.
- Management emphasized that beta sites have already been running the instrument in-house, including a reported 6.5-hour turnaround at one site, helping seed future adoption.
- The near-term revenue from registry and beta-site work is expected to be helpful but not material; the bigger revenue opportunity is the IVD kit launch after authorization.
- Reimbursement strategy is focused first on roughly 67 high-volume MolDX centers, while a nationwide price/code is hoped for in January 2028.
Andrea James said Q4 2025 operating expenses peaked when R&D reached $5.8 million, about $2 million above Q3, driven by lab supplies, consulting and FDA trial site costs. She said R&D fell to $3.8 million in Q3 2026, and operating expenses less noncash items were flat versus Q3 a year ago. She also said cash burn likely bottomed in Q2 2026. The company did not provide revenue or EPS figures on the call. On guidance, management expects both outside processes supporting the FDA response to finish before year-end 2026, then plans to submit the complete response before the January 21, 2027 deadline. If timing holds, management described launch as happening right after authorization, with heart testing potentially following via a 510(k) submission in the second half of 2027; Europe IVDR filing is targeted for late this year or early January, with review time of about 6 months.
Josh Riggs framed the quarter around two priorities: starting U.S. revenue from GraftAssure and finishing the FDA process. He said the company is moving from development toward commercialization, highlighted the new Head of Commercial hire, and repeatedly stressed that the product is being seeded with clinicians through beta sites, the FDA study sites, and the newly launched GALACTIC registry. His tone was constructive and confident, especially on FDA timing and the idea that local transplant testing is moving from centralized send-outs to in-house adoption.
Andrea James focused on the cost profile and transition from FDA spend to commercialization. She said operating expenses peaked in Q4 2025, with R&D at $5.8 million, then declined to $3.8 million in Q3 2026, and she noted operating expenses excluding noncash items were flat year over year in the third quarter. She said cash burn likely bottomed in Q2 2026 and tied future FDA programs to gross profit from the kidney transplant assay. She also said the company sees the U.S. regulated transplant testing market at $800 million, expects a nationwide price in January 2028, and views kitted products as the better model for Europe because lower reimbursement would largely pass through to IMDx.
Analysts pressed on what FDA’s pushback actually means, and management said the agency wanted more samples, more subgroup analysis, and additional outside studies, including independent accuracy work and a deeper biopsy-slide review. Josh Riggs said the company has tripled the sample set available since the original submission and believes it is in better shape to answer the FDA’s questions. Questions also focused on timing for launch, reimbursement, and whether revenue from the registry/beta sites would matter; management said those revenues should be real but not material, and that reimbursement efforts will initially concentrate on MolDX centers where the process is already established. In a separate thread, management said the heart program should be easier because it would follow a 510(k) path rather than de novo, with samples potentially gathered in the first half and submission later in the second half of 2027.
The bull case is that the FDA process appears to be de-risking rather than breaking, with management saying it has a path to respond by the January 21, 2027 deadline. The company also has visible commercial setup already in place: beta sites are trained, several centers are validating, registry enrollment has begun, and reimbursement pathways exist today in key MolDX markets.
The main risk is that FDA still said the submitted clinical data did not yet support the intended use, and management acknowledged the first submission was based on only about 75 samples. Commercial revenue before authorization appears limited, and management said registry and beta-site revenue will be helpful but not life-changing. Broader reimbursement outside MolDX remains uncertain, and Europe is constrained by limited payer coverage today.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 30.7%
- Shares Outstanding
- 32.76M
- Float Shares
- 10.05M
of shares held by institutions
41 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Broadwood Capital Inc | 12.68M | ▲ 753.04K |
| Awm Investment Company, Inc. | 2.77M | ▼ 64.93K |
| Vanguard Capital Management LLC | 731.39K | ▼ 4.46K |
| Vanguard Group Inc | 526.67K | ▲ 39.94K |
| Pura Vida Investments, LLC | 484.85K | ▼ 462.29K |
| Geode Capital Management, LLC | 270.56K | ▲ 13.65K |
| Vanguard Fiduciary Trust Co | 150.92K | ▲ 26.34K |
| Blackrock, Inc. | 148.53K | ▼ 2.00K |
| State Street Corp | 121.62K | ▲ 29.50K |
| Millennium Management LLC | 82.50K | ▼ 20.97K |
| Walleye Capital LLC | 57.59K | ▲ 57.59K |
| Northern Trust Corp | 49.09K | 0 |
Held by 23 ETFs
Biggest fund positions in IMDX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | SMITH PATRICK W | other | 1,142,857 |
| Nov 17, 26 | BROADWOOD PARTNERS, L.P. | buy | 3,428,571 |
| Nov 17, 26 | BROADWOOD PARTNERS, L.P. | buy | 0 |
| Jul 1, 26 | SILVERMAN LOU | other | 7,700 |
| Jul 1, 26 | Last Andrew J. | other | 7,700 |
| Jul 1, 26 | Arno Andrew | other | 12,100 |
| Jun 11, 26 | SILVERMAN LOU | other | 26,943 |
| Jun 11, 26 | Last Andrew J. | other | 26,943 |
| Jun 11, 26 | Arno Andrew | other | 32,331 |
| Apr 27, 26 | BROADWOOD PARTNERS, L.P. | buy | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IMDX coverage
Recent articles, reports, and earnings notes.
No research on IMDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMDX report →iMDx Expands GraftAssure Utilization as First Patient Samples Arrive for GALACTIC Registry Study
globenewswire.com · Nov 20
Insight Molecular Diagnostics Announces Pricing of $15 Million Public Offering
globenewswire.com · Nov 17
Insight Molecular Diagnostics Inc. (IMDX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 17
What Oncocyte (IMDX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 16
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
globenewswire.com · Nov 16
Insight Molecular Diagnostics Announces Proposed Public Offering
globenewswire.com · Nov 16
Aclaris Therapeutics (NASDAQ:ACRS) vs. Oncocyte (NASDAQ:IMDX) Financial Contrast
defenseworld.net · Nov 6
iMDx to Release Third Quarter Results on November 16, 2026
globenewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.